Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IM-1021

Phase 1Biologic

IImmunome, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid MalignanciesRecruiting

Solid MalignanciesPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Solid Malignancies

NCT06823167

Clinical

Trials by Indication[1]

Solid Malignancies1 trial

A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies

Recruiting·IImmunome, Inc.·Phase 1·NCT06823167·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IM-1021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IM-1021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IM-1021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunome, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IImmunome, Inc.

Related News